These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2049041)

  • 1. Anti-lipopolysaccharide antibodies in gram-negative bacteremia.
    Baumgartner JD
    Behring Inst Mitt; 1991 Feb; (88):216-21. PubMed ID: 2049041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Baumgartner JD
    Eur J Clin Microbiol Infect Dis; 1990 Oct; 9(10):711-6. PubMed ID: 2261915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.
    Pollack M; Huang AI; Prescott RK; Young LS; Hunter KW; Cruess DF; Tsai CM
    J Clin Invest; 1983 Dec; 72(6):1874-81. PubMed ID: 6358257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis.
    Klaerner HG; Dahlberg PS; Acton RD; Battafarano RJ; Uknis ME; Johnston JW; Dunn DL
    J Surg Res; 1997 May; 69(2):249-54. PubMed ID: 9224390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of endotoxemia and septicemia.
    Baumgartner JD; Glauser MP
    Immunobiology; 1993 Apr; 187(3-5):464-77. PubMed ID: 8330909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
    Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides.
    Parent JB; Gazzano-Santoro H; Wood DM; Lim E; Pruyne PT; Trown PW; Conlon PJ
    Circ Shock; 1992 Sep; 38(1):63-73. PubMed ID: 1382882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
    Ziegler EJ; McCutchan JA; Fierer J; Glauser MP; Sadoff JC; Douglas H; Braude AI
    N Engl J Med; 1982 Nov; 307(20):1225-30. PubMed ID: 6752708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
    Fink MP
    Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of type-specific and cross-reactive murine monoclonal antibodies directed against endotoxin during experimental sepsis.
    Dunn DL; Bogard WC; Cerra FB
    Surgery; 1985 Aug; 98(2):283-90. PubMed ID: 3895540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.
    Cross AS; Opal S; Cook P; Drabick J; Bhattacharjee A
    Vaccine; 2004 Feb; 22(7):812-7. PubMed ID: 15040932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoprotective murine monoclonal antibodies specific for the outer-core polysaccharide and for the O-antigen of Escherichia coli 0111:B4 lipopolysaccharide (LPS).
    Coughlin RT; Bogard WC
    J Immunol; 1987 Jul; 139(2):557-61. PubMed ID: 3298431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin.
    Ziegler EJ; McCutchan JA; Braude AI
    Eur J Cancer (1965); 1979; 15 Suppl():71-6. PubMed ID: 397063
    [No Abstract]   [Full Text] [Related]  

  • 19. An immunoprotective monoclonal antibody to lipopolysaccharide.
    Kirkland TN; Ziegler EJ
    J Immunol; 1984 May; 132(5):2590-2. PubMed ID: 6201551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipopolysaccharide microarrays for the detection of antibodies.
    Thirumalapura NR; Morton RJ; Ramachandran A; Malayer JR
    J Immunol Methods; 2005 Mar; 298(1-2):73-81. PubMed ID: 15847798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.